New Stock News | Lu Peng Pharmaceutical Reapplies to Hong Kong Stock Exchange
According to the disclosure by the Hong Kong Stock Exchange on May 28, Lopeng Pharmaceutical Co., Ltd. (referred to as Lopeng Pharmaceutical) submitted its listing application to the main board of the Hong Kong Stock Exchange, with CITIC Securities as its exclusive sponsor.
According to the disclosure on May 28 by the Hong Kong Stock Exchange, Lu Peng Pharmaceutical Co., Ltd. (referred to as Lu Peng Pharmaceutical) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC SEC as the exclusive sponsor. The company previously submitted an application for listing to the Hong Kong Stock Exchange on October 31, 2025. Lu Peng Pharmaceutical is a biopharmaceutical company with its own research and development platform BeyondX for oral drug chemistry, focusing on designing, discovering, clinically developing, and commercializing high bioavailability oral drugs for global cancer and autoimmune disease patients. The company has established a product pipeline consisting of six key candidate products, of which three are core assets in the new drug application stage and clinical stage, namely the core products LP-168, LP108, and LP-118.
Related Articles
YUM CHINA (09987): David Hoffmann appointed as a member of the Compensation Committee.
C FIN SERVICES (00605): Janie Lee has resigned as an independent non-executive director.
US Stock Market Move | Lilly (LLY.US) rises more than 5% as CVS Health Corporation's health recovery weight loss drug Zepbound is covered by medical insurance.
YUM CHINA (09987): David Hoffmann appointed as a member of the Compensation Committee.
C FIN SERVICES (00605): Janie Lee has resigned as an independent non-executive director.
US Stock Market Move | Lilly (LLY.US) rises more than 5% as CVS Health Corporation's health recovery weight loss drug Zepbound is covered by medical insurance.
